ArticleEuro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin2025
Early vaccine effectiveness estimates against medically attended laboratory-confirmed influenza based on influenza surveillance, Beijing, China, 2024/25 season.
Article in Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Influenza vaccine protection and contact patterns among outpatients with influenza-like illness during the 2024-2025 season in China: a test-negative case-control study.Journal of global health · 2026Article
- Influenza Vaccine Effectiveness Against Influenza A(H1N1)pdm09-Associated Hospitalizations With SARI in Beijing, China, in the 2024-2025 Season.Influenza and other respiratory viruses · 2026Article
- Modest protection from vaccination against influenza A(H3N2) subclade K, Beijing, China, 2025/26 season.Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin · 2026Article
- Moderate protection from vaccination against influenza A(H3N2) subclade K in Beijing, China, September to December 2025.Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin · 2026Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We estimated early influenza vaccine effectiveness (VE) for the 2024/25 season in outpatients, in Beijing using a test-negative design. A(H1N1)pdm09 dominated (99.3%), all sequenced strains (n = 38) clustered in clade 6B.1A.5a.2a, and 37 of 38 antigenically similar to the vaccine strain. VE against any influenza virus infection was 48.5% (95% CI: 34.8-59.5) and 48.7% (95% CI: 35.1-59.7) against A(H1N1)pdm09. Vaccination in the current or previous season against any influenza showed a VE of 52.5% to 54.9%, compared to no vaccination in both seasons.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.